MEREEarnings•globenewswire•
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
Sentiment:Negative (30)
Summary
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire